Intracoronary autologous CD34+ stem cell therapy for intractable angina
Background A large number of patients with coronary artery disease experience angina that is not suitable for revascularization and is refractory to conventional medical therapy.Laboratory and preclinical studies have provided evidence for the safety and potential efficacy of autologous CD34+ stem cell therapies as treatment for angina.Clinical studies investigating intramyocardial transplantation of autologous CD34+ stem cells by catheter injection for patients with refractory angina show that this is safe and feasible.It remains unclear whether intracoronary infusion of CD34+stem cells exert beneficial effects in patients with angina as well.We addressed this question with a controlled clinical trial by enrolling 112 patients with refractory angina.Previous trials have investigated the safety and beneficial effects of CD34+ cells isolated from granulocyte colony-stimulating factor-mobilized peripheral blood; in our trial, we isolated CD34+ cells directly from the patient”s bone marrow.
WANG Shi-hong CUI Jun-yu PENG Wei LU Min
General Hospital of Beijing Military Region of PLA,Beijing,China
国内会议
北京
英文
5-6
2013-03-20（万方平台首次上网日期，不代表论文的发表时间）